Investing in Oncology: Why Cancer Therapeutics and Diagnostics Remain the Largest Frontier in Life-Sciences Venture

Why is oncology the largest therapeutic area in biopharma?

Cancer is not one disease. It is a category of many distinct diseases unified by a common failure of cellular control, and that single fact explains most of what follows. Public-health data has long placed cancer among the leading causes of death worldwide, and because incidence generally rises with age, the burden tends to grow as populations live longer. The unmet need is not a single gap to be closed once. It is a moving frontier that regenerates as tumors evolve, as patients relapse, and as each solved problem exposes the next.

Oncology has become the largest area of drug development for structural reasons, not fashion. Industry pipeline data has for years shown cancer accounting for the largest single share of drugs in clinical development, and it is consistently among the most active categories for new approvals. Three forces compound. The biology is deep, so there is generally another target, another modality, or another resistance mechanism to address. The regulatory framework offers accelerated pathways and surrogate endpoints that can shorten the road to a first approval. And the willingness to pay for meaningful survival benefit is high. For an investor, the market has rarely been the question. The question is usually the science.

The implication for a pre-seed investor is subtle. Because oncology is so large and so well-funded downstream, the earliest capital is not primarily de-risking a commercial thesis. It is de-risking a biological one. Sonnerie’s job at the first institutional check is to judge whether a specific mechanistic insight is real, differentiated, and translatable, knowing that if it is, the capital markets above us are among the deepest in life sciences.

What is the scientific frontier in cancer therapeutics?

Modern oncology is best understood as a sequence of modality waves, each of which opened a new axis of attack on the disease. None fully replaced its predecessor. They accumulate, and the frontier is now unusually broad.

Targeted and precision therapy was an early departure from cytotoxic chemotherapy. Rather than acting on all dividing cells, these drugs inhibit a specific molecular driver, such as a mutated kinase or a fusion protein that the tumor depends on. Kinase inhibitors remain among the most productive categories of new cancer approvals. The precision-oncology premise is that the right drug matched to the right molecular alteration can produce deep responses with a tolerability profile that broad chemotherapy could rarely match. The limitation is equally precise. Tumors driven by a single lesion often find a way around a single-point inhibitor.

Immuno-oncology reframed the problem. Instead of acting directly on the tumor, checkpoint inhibitors release inhibitory signals on the patient’s own T cells, blocking pathways such as PD-1, PD-L1, or CTLA-4 so the immune system can better recognize and destroy cancer. This class has produced durable, sometimes long-lasting responses in diseases that were formerly difficult to treat, and the leading agents are among the best-selling medicines in the world. But checkpoint inhibitors benefit only a subset of patients across most tumor types, and a central unsolved problem is why. Much of the answer appears to lie in the tumor microenvironment, the immunosuppressive ecosystem of stroma, vasculature, and suppressor cells that keeps T cells out or turns them off.

Cell therapy went further, engineering the immune cell itself. In CAR-T therapy, a patient’s T cells are re-engineered to express a chimeric antigen receptor targeting a tumor marker, and this approach has delivered durable remissions in certain blood cancers. The frontier here is twofold. Extending cell therapy from blood cancers into solid tumors, where the microenvironment and antigen heterogeneity are far more challenging, and moving from bespoke autologous manufacturing toward allogeneic, off-the-shelf products that could make the modality more scalable.

Antibody-drug conjugates have been among the most commercially active modalities of the current cycle. An ADC is a targeting antibody chemically linked to a potent cytotoxic payload, designed to concentrate a cytotoxic agent in antigen-expressing tumor cells while relatively sparing healthy tissue. A growing number of ADCs are now approved, with newer agents and payload chemistries continuing to reach the market, and dealmaking in the category has been active. ADCs also blur the older line between targeted and cytotoxic therapy, and bystander-payload designs can reach some antigen-negative cells within a heterogeneous tumor.

A more recent wave is bispecific and multispecific biology. T-cell engagers physically bridge a T cell to a tumor cell, driving an immune synapse without relying on pre-existing anti-tumor immunity. Dual-targeting antibodies, including designs that pair checkpoint blockade with modulation of tumor vasculature, aim to address the infiltration and microenvironment problems that limited first-generation immunotherapy. This is where much of the mechanistic creativity, and much of the university science, now sits.

How is early cancer detection changing, and why does it matter for investors?

Therapeutics get the attention, but the diagnostics shift may be the larger long-term prize, because in oncology the stage at diagnosis is among the strongest determinants of survival. A cancer caught while localized is often treatable, sometimes with surgery alone. The same cancer caught after metastasis is frequently much harder to treat. Anything that reliably shifts diagnosis earlier can change outcomes at population scale.

Liquid biopsy is a key enabling technology. Tumors shed circulating tumor DNA, or ctDNA, and other analytes into the blood, and error-corrected next-generation sequencing combined with methylation and fragmentomic signatures can now detect these signals at very low allele frequencies. Three distinct use cases are emerging, and they carry very different regulatory and evidentiary burdens.

Minimal residual disease, or MRD, detection is among the more mature applications and, for a company builder, often the more tractable. After surgery or curative-intent treatment, a blood test that detects residual ctDNA can identify patients at higher risk of relapse before imaging shows anything. This is a molecularly defined, high-value use case with a clear potential clinical action, and prospective studies have been maturing the evidence base. Therapy selection and monitoring, using ctDNA to identify actionable alterations or track response, is a natural companion use.

Multi-cancer early detection, or MCED, is the most ambitious and the hardest. Screening largely asymptomatic populations demands very high specificity, because even a small false-positive rate can generate substantial downstream harm and cost across large numbers of healthy people. As a category, MCED remains investigational, is not a substitute for established guideline-based screening, and will require large prospective outcomes data to establish clinical utility. For a pre-seed investor, MCED is a long-horizon, capital-intensive thesis, whereas MRD and companion diagnostics can often reach clinical value on a tighter arc.

What are the real risks of investing in oncology?

Honesty about risk is part of the thesis, not a footnote to it. Oncology’s attractiveness is inseparable from its difficulty.

The field is crowded. Because the commercial logic is widely understood, popular targets attract many programs simultaneously. A mechanistically elegant story around a validated target can be scientifically sound and still be commercially crowded by the time it reaches the clinic. Differentiation has to be genuine and defensible, not a fast-follow on an already validated target.

The biology is heterogeneous and adaptive. Tumors are genomically unstable populations under selective pressure, which is much of why they respond and then resist. Resistance is not a failure mode that can be engineered away once. It is the expected endpoint of most single-mechanism therapies, and any durable thesis has to account for what the tumor does next, whether through combination strategy, a mechanism that is harder to bypass, or a target the tumor cannot easily route around.

Clinical development is long, expensive, and unforgiving. Oncology trials read out on hard biological endpoints, and the gap between a promising response rate in a small early study and a survival benefit in a randomized trial is where a large share of programs fail. Translational models are imperfect, and preclinical models frequently overstate human efficacy. None of this argues against oncology. It argues for underwriting the biology with unusual rigor at the point of entry.

What regulatory and clinical realities shape an oncology company?

Oncology has a distinctive regulatory grammar, and founders who understand it early tend to build more efficiently. The endpoints matter enormously. Objective response rate, or ORR, measures the fraction of patients whose tumors shrink by a defined threshold, and it can support accelerated approval because it reads out relatively quickly. Progression-free survival, or PFS, measures time until the disease worsens or the patient dies. Overall survival, or OS, measures time to death and remains the most definitive endpoint, but it takes longer and can be confounded by later therapies. The choice of endpoint shapes trial size, duration, and cost, and it is among the first strategic decisions a program makes.

Accelerated approval is a defining regulatory feature of oncology in the United States. It permits approval on a surrogate endpoint reasonably likely to predict clinical benefit, with confirmatory trials required afterward, and it has brought effective drugs to patients earlier than the traditional path would allow. It also carries obligations. Regulators have grown more insistent that confirmatory studies be underway and actually deliver, and programs that fail to confirm benefit can have that approval withdrawn.

Companion diagnostics are woven into many modern oncology approvals. A targeted therapy that works only in a molecularly defined subset is often approved alongside a validated test that identifies eligible patients. For a precision-oncology company this is not an afterthought. The diagnostic strategy, the biomarker hypothesis, and the therapeutic are best treated as a single integrated program, and getting that architecture right early is a mark of a sophisticated founding team.

What does a great pre-seed oncology spinout look like?

Sonnerie backs university spinouts at the first institutional check, so we see companies before most of the answers exist. What we look for is a small number of load-bearing signals.

A differentiated biological insight, often born from years of academic work, that is not merely a new asset against a known target but a genuinely new mechanism, a new target, a design that resists escape, or a modality advantage. In a crowded field, the insight has to be non-obvious enough that the crowd is not already there.

A translational data package proportionate to the stage, credible in vivo evidence, a clear and testable biomarker hypothesis, and an honest reading of where the biology is de-risked and where it is not. We are more persuaded by a team that can articulate exactly what would falsify their thesis than by one that has only ever seen confirming data.

A defensible path from target to patient, a clear-eyed view of the endpoint strategy, the eventual regulatory route, any companion-diagnostic requirement, and the resistance landscape. And clean foundations, meaning intellectual property properly assigned out of the university and a licensing structure that does not encumber the company’s future.

Above all, an operator-led founding team. Deep science is necessary but not sufficient. The spinouts that compound are those where scientific founders are paired with people who have actually built and run drug-development organizations, who know how to design a trial, manage a burn, and make the unglamorous decisions that turn a discovery into a therapy.

How does Sonnerie evaluate oncology opportunities?

Our lens is consistent with how we invest across healthcare and life sciences. We are a pre-seed and seed firm, we are frequently the first institutional check, and we are operator-led, which means we evaluate biology and buildability together rather than treating one as the other’s afterthought.

In oncology specifically, we underwrite four things. The biological thesis, is the mechanism real, and is the target credible. The differentiation, is this genuinely distinct from the crowd, or a fast-follow that will be commoditized. The translational package, does the early evidence justify the next experiment, and does the team understand its own weak points. And the team, can these founders navigate the specific and unforgiving path of oncology drug development, or attract the operators who can.

We are candid about what we do not do. We do not offer personalized investment advice, we do not make claims about returns, and we do not pretend the science is easier than it is. What we offer founders is an investor who can hear the signal in the noise early, who understands that in oncology the market is rarely the constraint and the biology usually is, and who is willing to write the first check when the science is right. From signal to scale, that is the work.